TYG oncology is a biotechnology company focused on the development of novel cancer immunotherapies using active checkpoint control. A “third-generation” cancer immunotherapy, the lead product candidate TYG100 will be ready to enter clinical trials for pancreatic and other gastrointestinal cancers after production and toxicology testing of the drug substance suitable for human use. TYG100 comprises the same gastrin antigen that was developed and validated by a predecessor company (Aphton Corporation) with positive Phase 3 pancreatic cancer trial results using Gastrimmune (G17DT), an immunotherapy product. With TYG100, the proven antigen is coupled with an improved immune-modulating carrier (IMC), namely the S-TIR™ Technology Platform. Fred Jacobs, Dr Paul Broome and Dr Geert Mudde worked at the same predecessor company and recognised the potential of developing a better pancreatic cancer immunotherapy targeting the same generic antigen coupled with a new innovative carrier derived from the S-TIR™ technology platform making the antigen significantly more immunogenic.

TYG100 demonstrated in primate studies a dramatically improved immune response that was around three times faster and approximately 1,000 times larger than the responses that had been observed with G17DT. In addition, TYG100 had a 100% positive response rate. A major issue with G17DT was that the majority of patients were either non- or low-responders. TYG100 demonstrates how the Company uses circulating protein ligands as therapeutic targets.

TYG has a pipeline of products to develop after TYG100 has successfully entered the clinic.

All the Company’s immunotherapies are based on the S-TIR™ technology platform, which was invented by co-founder Dr Geert Mudde.